S. Coats

发表

Discovery and evaluation of dual CDK1 and CDK2 inhibitors.

Juan Leal, Richard Kendall, T. Bush, 2006, Cancer research.

Cyclin E2, the cycle continues.

Marc Payton, S. Coats, Marc N. Payton, 2002, The international journal of biochemistry & cell biology.

Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle

James M. Roberts, J. Roberts, S. Coats, 1996, Science.

Cyclin E2, a Novel G1 Cyclin That Binds Cdk2 and Is Aberrantly Expressed in Human Cancers

M. Bass, S. Thukral, Marc Payton, 1999, Molecular and Cellular Biology.

Deregulation of Cyclin E2 expression and associated kinase activity in primary breast tumors

Marc Payton, Grace Chung, S. Coats, 2002, Oncogene.

Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells

Herren Wu, R. Woods, S. Coats, 2015, Cellular and Molecular Immunology.

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

J. Soria, S. Coats, D. Tice, 2019, Clinical Cancer Research.

EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner

Zhan Xiao, S. Coats, B. Jallal, 2012, Cancer biology & therapy.

A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.

Damon L. Meyer, D. Jackson, Herren Wu, 2008, Cancer research.

Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™

P. Kiener, M. Kinch, S. Coats, 2006, Molecular Cancer Therapeutics.

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

M. Tabrizi, D. Blakey, S. Coats, 2011, Cancer research.

The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA

Herren Wu, S. Coats, P. Baeuerle, 2012, PloS one.

Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.

P. Gallant, T. Bush, M. Morrison, 2010, Journal of medicinal chemistry.

Bispecific and Biparatopic Antibody Drug Conjugates

S. Coats, Changshou Gao, F. Comer, 2018 .

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.

P. Kufer, R. Lutterbuese, P. Kiener, 2007, Cancer research.

9th Annual European Antibody Congress, November 11–13, 2013, Geneva, Switzerland

T. Wurch, J. Reichert, A. Lugovskoy, 2014, mAbs.

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

Herren Wu, R. Woods, P. Kiener, 2009, Neoplasia.

Antibody-DependentCell-MediatedCytotoxicityEffector – Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors 1

Herren Wu, R. Woods, P. Kiener, 2009 .

lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin

James M. Roberts, G. Crabtree, J. Massagué, 1994, Nature.

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.

P. Kiener, M. Kinch, S. Coats, 2006, Molecular cancer therapeutics.

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas

S. Coats, P. Baeuerle, S. Hammond, 2014, mAbs.

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

M. Rebelatto, J. Osbourn, Herren Wu, 2016, Cancer cell.

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2–positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib

D. Jackson, S. Coats, B. Jallal, 2009, Molecular Cancer Therapeutics.

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.

Thomas Hartmann, Tom Boone, Juan Leal, 2004, Cancer cell.

MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.

R. Woods, S. Coats, B. Jallal, 2012, International journal of oncology.

Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis.

M. Nangaku, W. Couser, S. Shankland, 1996, Kidney international.

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

N. Bander, E. Corey, R. Tammali, 2018, Molecular Cancer Therapeutics.

A new pathway for mitogen-dependent Cdk2 regulation uncovered in p27Kip1-deficient cells

James M. Roberts, Grace Chung, S. Coats, 1999, Current Biology.

A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties

Vidyashankara G. Iyer, David M. Wilson, Richard Bean, 2016, PloS one.

Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1.

M. Nangaku, W. Couser, S. Shankland, 1997, Kidney international.

Detergent solubility defines an alternative itinerary for a subpopulation of PDGF β receptors

W. Pledger, S. Coats, M. Awazu, 1996, Journal of cellular physiology.

HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells.

A. Chang, M. Wicha, S. Coats, 2021, Cell chemical biology.

Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers

E. Hurt, M. Rebelatto, R. Tammali, 2018, Blood.

Antagonistes et agonistes d'alk et applications

A. Wellstein, Herren Wu, S. Coats, 2006 .

100 Inhibition of PDGFRalpha in tumor stroma with MEDI-575 enhances activity of carboplatin/paclitaxel and delays tumor regrowth in a NSCLC xenograft model

R. Baffa, S. Coats, B. Jallal, 2010 .

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

M. Rebelatto, J. Osbourn, Herren Wu, 2016, Cancer cell.

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

M. Tabrizi, D. Blakey, S. Coats, 2011, Cancer research.

Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2.

S. Coats, S. Gong, H. Gan, 2023, Nuclear medicine and biology.